BMC Neurology
Cure8 research brief
Why This Matters
A rare but serious neurological complication (Guillain–Barré syndrome) occurred alongside a severe UC flare after abrupt vedolizumab withdrawal, so people with UC should be aware that sudden neurologic weakness needs urgent evaluation.
Who Should Pay Attention
Adults with ulcerative colitis; gastroenterologists and neurologists involved in IBD care; caregivers of patients on biologic therapy.
Study Snapshot
Story typeResearch paper
Evidence typeResearch paper
Source depthJournal abstract
What To Know
This report links a severe UC flare and abrupt biologic discontinuation (vedolizumab) with onset of Guillain–Barré syndrome, an acute autoimmune neuropathy. The case emphasizes prompt neurologic evaluation when patients with UC develop acute progressive weakness, and early treatment with IVIg or plasma exchange alongside control of intestinal inflammation.
The authors suggest avoiding unplanned stopping of biologic therapy.
Keep In Mind
Single case report from a journal abstract; cannot prove that stopping vedolizumab caused GBS. The patient improved with IVIg and restarting vedolizumab, but this is observational and specific to one patient.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationBMC Neurology
PublisherSpringer Science and Business Media LLC
AuthorsAshiq Ali, Sana Arooj, Mohammad Adi +3 more
Study typeJournal Article
Indexed viaCrossref
Source typeResearch paper
PublishedSep 28, 2026, 12:00 AM
Content availableJournal abstract
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Fulminant Eosinophilic Myocarditis After Sequential Biologic Therapy in Ulcerative Colitis.
Biologic therapy and steroid withdrawal were temporally associated with severe eosinophilic myocarditis in a patient with ulcerative colitis — a life-threatening but potentially treatable complication. Early recognition...
Sweet’s syndrome during anti-TNF therapy with successful rescue using a JAK inhibitor in refractory ulcerative colitis: a case report and literature review
People with UC can develop severe neutrophilic skin complications like Sweet’s syndrome that may reflect active bowel inflammation even when recent tests suggested remission.
Mesalazine-induced myocarditis following dose escalation in ulcerative colitis: a diagnostic challenge
Mesalazine is commonly used in ulcerative colitis; recognizing rare but serious myocarditis linked to it can lead to rapid treatment changes and recovery. Distinguishing drug-induced myocarditis from IBD-related...